Buscar
Mostrando ítems 1-10 de 149
Type 2 diabetes: Prescription patterns and treatment outcomes of IDMPS survey in Argentina
(Elsevier Ireland, 2019-07)
Aim To assess prescription patterns for treatment of type 2 diabetes (T2D) and their outcomes in the IDMPS survey in Argentina. Methods Data from 2551 people with T2D recruited from 210 physicians participating in IDMPS ...
The validity of cost-effectiveness analyses of tight glycemic control. A systematic survey of economic evaluations of pharmacological interventions in patients with type 2 diabetes
(Springer, 2020)
PURPOSE: Currently available randomized trial evidence has shown no reductions in type 2 diabetes (T2D) complications important to patients with tight glycemic control. Yet, economic analyses consistently find tight ...
Inércia clínica na intensificação da terapia com insulina em pacientes com Diabetes mellitus tipo 2 de um centro de diabetes público, terciário e com limitações no arsenal terapêutico farmacológico
(Universidade Federal de São Paulo (UNIFESP), 2019-02-28)
Background: Clinical inertia is related to the difficulty of achieving and maintaining optimal glycemic control. It has been extensively studied the delay of the period to insulin introduction in type 2 diabetes mellitus ...
Frequency of self-monitoring blood glucose and attainment of HbA1c target values
(Springer, 2015-04)
Aims: Test strips for self-monitoring of blood glucose (SMBG) represent in Argentina, around 50 % of diabetes treatment cost; the frequency of their use is closely associated with hyperglycemia treatment. However, the ...
Biphasic insulin aspart for the management of diabetic patients with unsatisfactory metabolic control Tratamiento con insulina aspártica bifásica en pacientes con diabetes en mal control metabólico. Experiencia clínica programada
(2007)
Background: Biophasic insulin aspart (InAsBi) is a mixture of 30% of rapid acting soluble aspart insulin and 70% aspart insulin retarded with protamine. The soluble portion reduces postprandial serum glucose rises and the ...
Treat-to-target HbA1c and lipid profile to prolong β-cell mass/function and optimize treatment goal attainment
(John Wiley & Sons Ltd, 2019-05)
Background: To evaluate the relation between different serum lipid fractions and other known barriers to attain the HbA1c ≤ 7.0% (53 mmol/mol) target. Methods: Data on 2719 patients with type 2 diabetes were collected from ...
Análise do papel da metformina na via insulínica, não-insulínica e inflamatória
(Universidade Federal de UberlândiaBRPrograma de Pós-graduação em Genética e BioquímicaCiências BiológicasUFU, 2016)